SA3Ag vaccine

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Bacterial InfectionsImmunotherapy, ActiveStaphylococcal InfectionsStaphylococcal Skin InfectionsStaphylococcal Vaccines

Phase 1

An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

CompletedNCT01018641

PfizerBacterial Infections, Immunotherapy, Active, Staphylococcal Infections +2

Start: 2010-01-31End: 2011-07-31Updated: 2014-04-24

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

CompletedNCT01643941

PfizerStaphylococcal Infections

Start: 2012-08-31End: 2014-03-31Updated: 2019-03-04

Related Papers

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)

Open Forum Infectious Diseases2019-12-2420 citations

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial

Vaccine2016-11-1753 citations

Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.

2016-08-098 citations